Metastatic Solid Tumors clinical trials

Explore recruiting metastatic solid tumors clinical trials.

Recruiting metastatic solid tumors studies right now

Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record

Also recruiting in Europe

Metastatic Solid Tumors trials registered in the EU Clinical Trials Information System (CTIS). These are outside the "near me" matcher above - open a study for full details.

Phase 1 Study of OP-3136 in Advanced or Metastatic Solid Tumors

Ireland, Spain, France

Human Pharmacology (Phase I)- First administration to humans EU CTIS Study details

A Phase 2 Open-Label Study of Sacituzumab Govitecan (IMMU-132) in Subjects with Metastatic Solid Tumors

France, Spain, Belgium

Therapeutic exploratory (Phase II) EU CTIS Study details

A Phase I/II Open-label Dose Escalation and Dose Expansion Study to Evaluate the Safety, Pharmacokinetics, Pharmacodynamics, and Efficacy of AZD5863, a T cell-engaging Bispecific Antibody that Targets Claudin 18.2 (CLDN18.2) and CD3 in Adult Participants with Advanced or Metastatic Solid Tumors.

Netherlands, France

Phase I and Phase II (Integrated)- First administration to humans EU CTIS Study details

Tumor-Agnostic Precision Immuno-Oncology and Somatic Targeting Rational for You (TAPISTRY) Phase II Platform Trial

France, Belgium, Poland, Germany, Portugal, Denmark +2 more

Therapeutic exploratory (Phase II) EU CTIS Study details

Open-label Rollover Study to Evaluate Long-Term Safety in Subjects with Metastatic Solid Tumors that are Benefiting from Continuation of Therapy with Sacituzumab Govitecan

Spain, Belgium, France

Therapeutic use (Phase IV) EU CTIS Study details

TEMPLE - Thiopurine Enhanced Mutations for PD-1/​Ligand-1 Efficacy

Denmark

Phase I and Phase II (Integrated)- First administration to humans EU CTIS Study details

Metastatic Solid Tumors trials by city

Metastatic Solid Tumors in Toronto Metastatic Solid Tumors in Vancouver Metastatic Solid Tumors in Montreal Metastatic Solid Tumors in Calgary Metastatic Solid Tumors in Edmonton Metastatic Solid Tumors in Ottawa Metastatic Solid Tumors in Winnipeg Metastatic Solid Tumors in Quebec City Metastatic Solid Tumors in Hamilton Metastatic Solid Tumors in Kitchener Metastatic Solid Tumors in London Metastatic Solid Tumors in Halifax Metastatic Solid Tumors in New York Metastatic Solid Tumors in Los Angeles Metastatic Solid Tumors in Chicago Metastatic Solid Tumors in Houston

Other conditions

Obesity Type 2 diabetes Type 1 diabetes Prediabetes Weight loss Metabolic syndrome High cholesterol High triglycerides High blood pressure PCOS Hypothyroidism Thyroid disease Gout Fatty liver disease (NAFLD/NASH) Heart failure Coronary artery disease Atrial fibrillation Stroke Stroke recovery Peripheral artery disease Pulmonary hypertension Deep vein thrombosis Chronic kidney disease Diabetic kidney disease